• About
    • Company Overview
    • Management
    • Board of Directors
    • Advisory Board
  • Collaborations
    • Partner Collaborations
    • Scientific & Research Collaborations
  • Patients
    • Patients Overview
    • Current Studies
      • Sponsored
        • TakeAim Lymphoma
        • TakeAim Leukemia
    • Understanding Primary CNS Lymphoma
    • Compassionate Use Policy
  • Pipeline
    • Pipeline Overview
    • CA-4948
    • Fimepinostat
    • CA-170
    • CA-327
  • Scientific Resources
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Financial Information
      • SEC Filings
      • Annual Reports
      • IRS Form 8937
    • Stock Performance
      • Historical Stock Lookup
      • Analyst Coverage
    • Contact Us
  • Careers
    • Life at Curis
    • Open Positions
    • Benefits
  • Contact
  • About
    • Company Overview
    • Management
    • Board of Directors
    • Advisory Board
  • Collaborations
    • Partner Collaborations
    • Scientific & Research Collaborations
  • Patients
    • Patients Overview
    • About Clinical Studies
    • Current Studies
      • Sponsored
        • TakeAim Lymphoma
        • TakeAim Leukemia
    • Studies Now Enrolling
  • Pipeline
    • Pipeline Overview
    • CA-4948
    • Fimepinostat
    • CA-170
    • CA-327
  • Scientific Resources
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports
      • IRS Form 8937
    • Stock Performance
    • Contact Us
  • Careers
    • Life at Curis
    • Open Positions
    • Benefits
  • Contact

SEC Filings

NASDAQCRIS
YearTrailing 12-MonthsCalendar Year 2026Calendar Year 2025Calendar Year 2024Calendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014Calendar Year 2013
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
ARSAn annual report to security holders.Apr 21, 2026Open An annual report to security holders. in HTML.Open An annual report to security holders. in DOC file.Open An annual report to security holders. in PDF file.Open An annual report to security holders. in XLS file.
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 24, 2026Open Annual report which provides a comprehensive overview of the company for the past year in HTML.Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.Open Annual report which provides a comprehensive overview of the company for the past year in XBLR Viewer.Open Annual report which provides a comprehensive overview of the company for the past year in XBLR file.
© Curis, Inc. 2026 - All Rights Reserved
  • Terms of Use
  • Privacy Policy
  • About
    • Company Overview
    • Management
    • Board of Directors
    • Advisory Board
  • Collaborations
    • Partner Collaborations
    • Scientific & Research Collaborations
  • Patients
    • Patients Overview
    • Current Studies
      • Sponsored
        • TakeAim Lymphoma
        • TakeAim Leukemia
    • Understanding Primary CNS Lymphoma
    • Compassionate Use Policy
  • Pipeline
    • Pipeline Overview
    • CA-4948
    • Fimepinostat
    • CA-170
    • CA-327
  • Scientific Resources
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports
      • IRS Form 8937
    • Stock Performance
    • Contact Us
  • Careers
    • Life at Curis
    • Open Positions
    • Benefits
  • Contact